Axsome Therapeutics (AXSM) Advances To Cross $100-Mark

Axsome Therapeutics Inc.'s (AXSM) phase II/III trial of investigational drug AXS-05 in Alzheimer's disease agitation has met the primary endpoint.

from RTT - Biotech https://ift.tt/2KC5SgP
via IFTTT